Project description
Research training network in incurable prostate cancer
Prostate cancer (PC) is a global health concern, and the treatment in cases of resistant cancer relapse following previous hormone therapy remains a challenge. The Marie Skłodowska-Curie Actions-funded TransPot project is a research training network designed to study incurable PC. The objective of the network is to provide training for a group of young researchers to become translational scientists in cancer biology, biomarker discovery, and therapeutic development. The goals include gaining a better understanding of treatment-resistant PC, identifying new strategies to overcome resistance, developing new tests to predict cancer response to treatment, and defining holistic tools for individual patients with treatment-resistant PC.
Objective
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).
The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.
Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:
1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.
2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.
3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.
We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineurology
- medical and health sciencesbasic medicineimmunology
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
G12 8QQ Glasgow
United Kingdom
See on map
Participants (10)
NE1 7RU Newcastle Upon Tyne
See on map
BT7 1NN Belfast
See on map
20014 Turku
See on map
3015 GD Rotterdam
See on map
Participation ended
30659 Hannover
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
115 27 Athina
See on map
33100 Tampere
See on map
2333 BZ Leiden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
BT63 5QD CRAIGAVON
See on map
93053 REGENSBURG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (6)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
G1 1XQ Glasgow
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SE1 2QN London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
00014 Helsingin Yliopisto
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3011 Bern Bern
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SW14 8JN London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
E20 1JQ LONDON
See on map